Drug intelligence / Profile preview

GTI-334.1

Development stage: Preclinical
Lead developer: GSNO Therapeutics
Modality: Small Molecules

Overview

GTI-334.1 is a chemical drug candidate developed by GSNO Therapeutics for the treatment of immune system diseases, cardiovascular diseases, digestive system disorders, and nonalcoholic steatohepatitis. The compound is currently in preclinical development and has not yet entered clinical trials or received regulatory approval. Its specific mechanism of action and molecular targets have not been publicly disclosed as of June 2025[1][3][4]. Indications under investigation include asthma, idiopathic pulmonary fibrosis, cardiovascular diseases, and nonalcoholic steatohepatitis[1][3][4].

Targets

GSNOR (S-nitrosoglutathione reductase)

Beyond the preview

Go deeper on GTI-334.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTI-334.1.

Explore the full profile